腺苷脱氨酶
腺苷脱氨酶缺乏症
脱氧腺苷
PEG比率
聚乙二醇
免疫系统
腺苷
三磷酸腺苷
严重联合免疫缺陷
免疫缺陷
免疫学
化学
医学
CD8型
AMP脱氨酶
药理学
生物化学
内科学
经济
基因
财务
作者
C. Bory,Roselyne Boulieu,G Souillet,M S Hershfield
出处
期刊:PubMed
[National Institutes of Health]
日期:1991-07-01
卷期号:46 (4): 323-6
被引量:2
摘要
The effect of polyethylene glycol-adenosine deaminase (PEG-ADA) therapy on biochemical, immunological and clinical abnormalities in an ADA-deficit child with severe combined immunodeficiency has been studied. Following PEG-ADA therapy, total lymphocytes, lymphocyte subsets (CD3, CD4 and CD8) and the response of lymphocytes to non specific mitogens increase significantly. The improvement of immunological functions is closely related to a decrease of erythrocyte deoxyadenosine triphosphate (dATP) concentrations. This study shows that PEG-ADA therapy is sufficiently effective to reduce and to maintain erythrocyte dATP levels at values compatible with normal immune functions. PEG-ADA represents an important progress for the treatment of ADA deficiency associated with severe combined immunodeficiency disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI